助手标题  
全文文献 工具书 数字 学术定义 翻译助手 学术趋势 更多
查询帮助
意见反馈
   hepatitis recurrence 的翻译结果: 查询用时:0.008秒
图标索引 在分类学科中查询
所有学科
外科学
更多类别查询

图标索引 历史查询
 

hepatitis recurrence
相关语句
  肝炎复发
     Reduce hepatitis recurrence, improve the survival rate of liver transplantation
     减少肝炎复发,提高肝移植存活率
短句来源
     Results The possible courses of hepatitis recurrence and liver dysfunction after renal transplantation lies in viral replication after immuno-suppression and medical toxicity.
     结果肾移植术后肝炎复发、肝功能衰竭的主要原因可能与免疫抑制后病毒活动以及药物毒性有关。
短句来源
  “hepatitis recurrence”译为未确定词的双语例句
     Results The hepatitis recurrence rate for the patients who had stopped taking the Laminvudine was 14.4%.
     结果拉米夫定停药后肝炎的总发生率为14·4%。
短句来源
  相似匹配句对
     Hepatitis C recurrence after liver transplantation.
     肝移植后丙型肝炎的复发及治疗
短句来源
     ANALYSIS OF THE HEPATITIS B RECURRENCE AFTER LIVER TRANSPLANTATION
     肝移植术后乙肝复发的临床特点分析
短句来源
     (4) recurrence;
     (4 )边缘复发 ;
短句来源
     Hepatitis C and Detection for it
     丙型肝炎及其检测
短句来源
     Die Hepatitis G
     庚型肝炎
短句来源
查询“hepatitis recurrence”译词为用户自定义的双语例句

    我想查看译文中含有:的双语例句
例句
为了更好的帮助您理解掌握查询词或其译词在地道英语中的实际用法,我们为您准备了出自英文原文的大量英语例句,供您参考。
  hepatitis recurrence
The aim of this study was to report the influence of hepatitis C virus (HCV) genotype and rejection episodes on the outcome of orthotopic liver transplantation (OLT), hepatitis recurrence, and progression to graft cirrhosis after OLT.
      


Liver transplantation is considered an effective form of therapy for patients with end stage liver disease. Unfortunately the results of transplantation for patients with chronic viral hepatitis have not been as promising as for other liver disorders. A high rate of hepatitis recurrence in the allograft leading to a higher incidence of graft and patient loss have led many transplant centers to reconsider the use of orthotopic liver transplantation (OLTX) in these groups. Current strategies to prevent...

Liver transplantation is considered an effective form of therapy for patients with end stage liver disease. Unfortunately the results of transplantation for patients with chronic viral hepatitis have not been as promising as for other liver disorders. A high rate of hepatitis recurrence in the allograft leading to a higher incidence of graft and patient loss have led many transplant centers to reconsider the use of orthotopic liver transplantation (OLTX) in these groups. Current strategies to prevent hepatitis B infection focus on identifying groups of hepatitis B virus (HBV) patients with lower risks of reinfection, specifically those with lack of markers for active HBV replication. Trials to convert “high risk” HBV patients to a “low risk” group have recently been initiated in the “high risk” group of patients with the aim to convert their HBV status from replicating to non or low replicating states. Antiviral agents or immunostimulatory therapy before and/or after OLTX have been proposed as a means to minimize recurrence of hepatitis B in the liver allograft. While the focus has been specific issues related to prevention or treatment of viral hepatitis in OLTX patients, there are still a number of areas for investigation. For example, immunosuppression is considered to play a role in the recurrence and chronicity of HBV and hepatitis C virus (HCV) in the liver allograft, especially since corticosteroids have been demonstrated to have a biologic effect on HBV by inducing HBV antigen synthesis. Moreover, most of the results to date are based on the use of cyclosporin A as the primary agent of immunosuppression. Tacrolimus (FK506) based immunosuppression may also prove to have a beneficial effect for HBV patients undergoing OLTX. By minimizing or eliminating the need for corticosteroids, FK506 based immunosuppression may lessen the risk of recurrence or the severity of hepatitis in the liver allograft in HBV patients, and ultimately improve patient and graft survival. The controversies in the use of OLTX for HBV and HCV have persisted, in spite of an appreciation for the risks associated with selection, prophylaxis and treatment of candidates with HBV, principally due to the uncertainties associated with OLTX for HCV. The routine application of OLTX to HBV candidates with low or no levels of HBV replication appears justified, however patients with active HBV replication should undergo OLTX only in a setting where new strategies for prevention, prophylaxis or treatment are being tested. Recently, the U.S. Department of Health and Human Services has approved OLTX for HBV, reflecting the improvements made in the clinical arena. However, further advances are needed for HCV prophylaxis and treatment of recurrent hepatitis following OLTX.

肝移植是治疗终末期肝脏疾病病人的最有效手段。不幸的是 ,慢性病毒性肝炎病人肝移植术后的结果并不像其他肝脏疾病那样理想 ,其主要原因是移植肝脏肝炎复发率高 ,最终导致移植肝脏功能衰竭 ,甚至受体死亡。因此 ,世界上许多器官移植中心对这类病人实施原位肝移植 ,进行重新考虑和评价。目前 ,预防乙型肝炎再感染的措施主要集中在那些具有较低再感染机会的乙型肝炎病人 ,特别是那些缺乏启动并激活HBV复制因素的病人。最近的实验研究主要致力于转变“高危”HBV感染病人为“低危”感染病人 ,其目的是将“高危”病人从HBV高复制状态转变为HBV不复制或低复制状态。在肝移植术前和术后应用抗病毒药物和免疫刺激剂治疗已成为减少移植后乙型肝炎再感染的有效方法。虽然防治肝移植病人肝炎病毒感染的研究已经取得了许多突破 ,但仍存在许多需进一步研究的领域。例如 ,免疫抑制剂被认为在肝移植病人的HBV和HCV再感染和慢性迁延性感染中发挥作用。值得注意的是 ,许多研究显示皮质类固醇激素具有诱导HBV抗原合成的生物活性。另外 ,目前的大部分研究结果均来源于环孢素A作为主要免疫抑制剂。现已证明在HBV感染病人实施肝移植后 ,更适合应用他克莫司 (Tacr...

肝移植是治疗终末期肝脏疾病病人的最有效手段。不幸的是 ,慢性病毒性肝炎病人肝移植术后的结果并不像其他肝脏疾病那样理想 ,其主要原因是移植肝脏肝炎复发率高 ,最终导致移植肝脏功能衰竭 ,甚至受体死亡。因此 ,世界上许多器官移植中心对这类病人实施原位肝移植 ,进行重新考虑和评价。目前 ,预防乙型肝炎再感染的措施主要集中在那些具有较低再感染机会的乙型肝炎病人 ,特别是那些缺乏启动并激活HBV复制因素的病人。最近的实验研究主要致力于转变“高危”HBV感染病人为“低危”感染病人 ,其目的是将“高危”病人从HBV高复制状态转变为HBV不复制或低复制状态。在肝移植术前和术后应用抗病毒药物和免疫刺激剂治疗已成为减少移植后乙型肝炎再感染的有效方法。虽然防治肝移植病人肝炎病毒感染的研究已经取得了许多突破 ,但仍存在许多需进一步研究的领域。例如 ,免疫抑制剂被认为在肝移植病人的HBV和HCV再感染和慢性迁延性感染中发挥作用。值得注意的是 ,许多研究显示皮质类固醇激素具有诱导HBV抗原合成的生物活性。另外 ,目前的大部分研究结果均来源于环孢素A作为主要免疫抑制剂。现已证明在HBV感染病人实施肝移植后 ,更适合应用他克莫司 (Tacrolimus,FK5 0 6 )。通过减少甚至停止皮质类固醇的使用 ,FK5 0

Objective To study the incidence, clinical features, mechanism, prevention and treatment of recurrence of hepatitis after stopping Laminvudine. Methods A one-year follow-up visit was made on the hepatitis patients who had a long-term application of Laminvudine and now had stopped it. Results The hepatitis recurrence rate for the patients who had stopped taking the Laminvudine was 14.4%. Conclusion For the patients who have a long-term application of Laminvudine, whether the serum transformation happen...

Objective To study the incidence, clinical features, mechanism, prevention and treatment of recurrence of hepatitis after stopping Laminvudine. Methods A one-year follow-up visit was made on the hepatitis patients who had a long-term application of Laminvudine and now had stopped it. Results The hepatitis recurrence rate for the patients who had stopped taking the Laminvudine was 14.4%. Conclusion For the patients who have a long-term application of Laminvudine, whether the serum transformation happen or not, the liver function still should be continuously monitored. For the recurred patients of hepatitis who have stopped taking the Laminvudine, the Laminvudine or Dycyrrhizin Preparation should be used again.

目的探讨拉米夫定停药后肝炎的发生率、临床特点、机理及防治。方法对长期应用拉米夫定治疗后停药的患者进行1年以上的随访。结果拉米夫定停药后肝炎的总发生率为14·4%。结论对长期应用拉米夫定治疗的患者无论是否发生血清转换而停药,都要继续监测肝功能;对发生停药后肝炎患者,可再次使用拉米夫定或甘草酸类制剂治疗。

Objective Analyse the course of the hepatitis relapse in renal transplant recipients and discuss the possible means of decreasing recurrence. Methods Virus signs' changes,drug concentration,period of treatment and prognosis were observed in those renal transplant recipients in hospital. Results The possible courses of hepatitis recurrence and liver dysfunction after renal transplantation lies in viral replication after immuno-suppression and medical toxicity.Conclusion Basing on liver function,medical...

Objective Analyse the course of the hepatitis relapse in renal transplant recipients and discuss the possible means of decreasing recurrence. Methods Virus signs' changes,drug concentration,period of treatment and prognosis were observed in those renal transplant recipients in hospital. Results The possible courses of hepatitis recurrence and liver dysfunction after renal transplantation lies in viral replication after immuno-suppression and medical toxicity.Conclusion Basing on liver function,medical concentration, and HBV-DNA,HCV-RNA termly measured, the quantity of immunodepressor should be properly regulated,anti-viral medicine should be added in time. It is very important for finding state of an illness changing and avoiding liver dysfunction.

目的分析肾移植术后患者肝炎复发的原因,并探讨可能减少复发的办法。方法观察肾移植术后肝炎复发的8例住院患者,其病毒标志物变化及应用药物、药物浓度、疗程和预后。结果肾移植术后肝炎复发、肝功能衰竭的主要原因可能与免疫抑制后病毒活动以及药物毒性有关。结论对移植术后肝炎复发患者定期监测肝功能、药物浓度和HBV-DNA、HCV-RNA等病毒标志物的变化,并根据肝功能情况适当调整免疫抑制剂的药量,及时加用抗病毒药物,对及时发现病情变化、避免肝功能衰竭是非常重要的。

 
图标索引 相关查询

 


 
CNKI小工具
在英文学术搜索中查有关hepatitis recurrence的内容
在知识搜索中查有关hepatitis recurrence的内容
在数字搜索中查有关hepatitis recurrence的内容
在概念知识元中查有关hepatitis recurrence的内容
在学术趋势中查有关hepatitis recurrence的内容
 
 

CNKI主页设CNKI翻译助手为主页 | 收藏CNKI翻译助手 | 广告服务 | 英文学术搜索
版权图标  2008 CNKI-中国知网
京ICP证040431号 互联网出版许可证 新出网证(京)字008号
北京市公安局海淀分局 备案号:110 1081725
版权图标 2008中国知网(cnki) 中国学术期刊(光盘版)电子杂志社